Amgen, Regeneron Stress PSCK9 Drugs' Value After Study Finds Major Overpricing

The makers of the two recently approved PSCK9 cholesterol-lowering drugs played up their products' “significant” value to high-risk patients after a non-profit group this week concluded the products are significantly overpriced and unaffordable to health plans. The non-profit research group that analyzed the effectiveness and price of the new class of LDL cholesterol-lowering medications found their value-based prices to be roughly three times the existing wholesale cost, and seven times over the price needed to fall within the current budget...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.